Testosterone (All Esters): The Complete Guide
The foundational anabolic-androgenic steroid. Androgen receptor pharmacology, ester pharmacokinetics, dose-response data from TRT through supraphysiological ranges, full risk profile, and evidence-based bloodwork protocols.
The Reference Anabolic-Androgenic Steroid Against Which All Others Are Measured
Testosterone is the primary male sex hormone and the foundation of every anabolic-androgenic steroid protocol. It is a Schedule III controlled substance in the United States, prescribed clinically for hypogonadism (testosterone replacement therapy) and used off-label or illegally for physique and performance. Exogenous testosterone binds the androgen receptor with identical affinity to your own testosterone, goes through the same metabolic conversions (aromatization to estradiol, 5-alpha reduction to DHT), and produces the same spectrum of anabolic, androgenic, and estrogenic effects.
At physiological replacement doses (100-200 mg/week), testosterone restores normal hormonal function with a manageable side effect profile when monitored via bloodwork. At supraphysiological doses (300-1000+ mg/week), testosterone drives dose-dependent gains in lean mass, strength, and nitrogen retention, along with dose-dependent increases in estrogenic side effects, androgenic side effects, cardiovascular strain, and complete HPTA suppression. The risk-benefit ratio shifts substantially across dosing tiers. This article presents the evidence for all tiers without advocacy.
What Is Testosterone? Classification and Endocrine Identity
Ester Overview
Testosterone esters are made by attaching a carboxylic acid chain to the 17-beta hydroxyl group. The ester does not change the testosterone molecule itself — it controls how fast the compound releases from the intramuscular depot. Once tissue esterases cleave the ester, the same free testosterone enters circulation. Longer esters produce slower, more sustained release. Shorter esters produce faster peaks and need more frequent injection.
| Ester | Half-Life | Injection Frequency | Common Use |
|---|---|---|---|
| No ester (Suspension) | 2-4 hours (aqueous) | Daily or twice daily | Pre-competition; rapid clearance |
| Propionate | 0.8 days | Every other day | Short cycles; blood level stability |
| Phenylpropionate | 1.5 days | Every other day | Component of Sustanon blend |
| Isocaproate | 4 days | Twice weekly | Component of Sustanon blend |
| Enanthate | 4.5 days | Every 3.5-7 days | Most common clinical and enhancement ester |
| Cypionate | 5 days | Every 3.5-7 days | Primary TRT ester (US); interchangeable with enanthate |
| Decanoate | 7.5 days | Weekly | Component of Sustanon blend |
| Undecanoate (injectable) | 20.9 days | Every 10-14 weeks (Nebido) | Long-acting TRT; fewer injections |
| Undecanoate (oral) | 3-4 hours (oral) | Twice daily with fat | Oral TRT (Jatenzo); lymphatic absorption |
| Gel / Transdermal | N/A (continuous) | Daily application | TRT; steady-state levels; transfer risk |
Ester weight correction: The ester adds molecular weight. Testosterone enanthate is about 72% testosterone by weight; cypionate is about 70%; propionate is about 84%; undecanoate is about 63%. When comparing doses across esters, the actual testosterone delivered per milligram differs. 200 mg of enanthate delivers about 144 mg of free testosterone; 200 mg of propionate delivers about 168 mg.
Mechanism of Action — AR Binding, Aromatization, 5-Alpha Reduction
Testosterone produces its effects through three primary pathways: direct androgen receptor activation, conversion to estradiol via aromatase, and conversion to dihydrotestosterone via 5-alpha reductase. Understanding these three is essential for reading both the benefits and the side effect profile of exogenous testosterone at any dose.
Androgen Receptor Binding (Direct Pathway)
This is the main event. Testosterone enters a muscle cell, locks onto the androgen receptor (AR), and the receptor carries the signal straight into the nucleus. Once there, it turns on the genes responsible for building muscle.
The downstream effects: more protein synthesis, less protein breakdown, activation of satellite cells (the muscle's built-in stem cell reserve), and higher IGF-1 expression inside muscle tissue. This is the pathway that builds tissue.
One detail that matters: androgen receptor density in muscle increases with both resistance training and androgen exposure. More testosterone means more receptors to receive it — a self-reinforcing loop that partly explains why supraphysiological doses produce supraphysiological results.
Aromatization to Estradiol (Estrogenic Pathway)
A portion of every testosterone molecule gets converted to estradiol (E2) by the enzyme aromatase. This happens mostly in fat tissue, brain, liver, and bone.
At normal testosterone levels, this is beneficial. Estradiol maintains bone density, supports healthy HDL cholesterol, protects the brain, and contributes to libido. Estrogen is not the enemy — it is essential.
At supraphysiological testosterone levels, the math changes. More testosterone means more aromatization, which means more estradiol. When E2 climbs too high, the consequences include gynecomastia (breast tissue growth), water retention, mood swings, and higher blood pressure. Higher body fat speeds this conversion up because fat cells produce more aromatase.
This is the pathway targeted by aromatase inhibitors (anastrozole, letrozole) — though their use carries its own risk tradeoffs.
5-Alpha Reduction to DHT (Androgenic Pathway)
Testosterone also gets converted to dihydrotestosterone (DHT) by 5-alpha reductase — an enzyme concentrated in the skin, prostate, and hair follicles.
DHT is testosterone's more aggressive cousin. It binds the androgen receptor with 3-5 times greater affinity and holds on longer. In androgen-sensitive tissues, that stronger signal produces the androgenic side effects: acne, faster scalp hair loss in genetically predisposed people, prostate growth, and more body hair.
DHT does not convert to estrogen, which is why DHT-derived compounds (like masteron or primobolan) carry androgenic but not estrogenic risk. 5-alpha reductase inhibitors (finasteride, dutasteride) block this conversion but come with their own side effect profile that needs careful evaluation.
Non-Genomic Signaling
Beyond the nucleus-level gene activation above, testosterone triggers rapid effects through separate membrane receptors — within seconds to minutes rather than hours.
These fast-acting pathways influence vasodilation, neurotransmitter release, and acute metabolic signaling. They likely contribute to the immediate mood and energy effects people report with testosterone, though the research here is still developing.
SHBG and Free Testosterone
About 98% of circulating testosterone is bound — roughly 60-70% to sex hormone-binding globulin (SHBG) and 25-35% to albumin. Only 1-3% circulates as free (unbound) testosterone, which is the biologically active fraction that enters cells and activates the AR. SHBG-bound testosterone is essentially inactive. Factors that raise SHBG (aging, hyperthyroidism, liver disease, oral estrogen) reduce free testosterone; factors that lower SHBG (obesity, insulin resistance, exogenous androgens) increase it. Exogenous testosterone at supraphysiological doses suppresses SHBG production, which disproportionately increases the free testosterone fraction.
Erythropoiesis
Testosterone stimulates red blood cell production through multiple mechanisms: direct stimulation of erythroid progenitor cells in bone marrow, more erythropoietin (EPO) production in the kidney, and better iron incorporation into hemoglobin. This increases red blood cell mass and hematocrit. At TRT doses, the effect is clinically beneficial for anemia of hypogonadism. At supraphysiological doses, hematocrit can rise above 54% — the threshold where blood viscosity increases clot risk (stroke, deep vein thrombosis, pulmonary embolism). Hematocrit monitoring is mandatory on any testosterone protocol.
graph TD T["Testosterone
Free, unbound"] T -->|"Aromatase
CYP19A1"| E2["Estradiol (E2)"] T -->|"5-Alpha Reductase
Type I/II"| DHT["DHT
3-5x AR affinity"] T -->|"Direct binding"| AR["Androgen Receptor
Nuclear translocation"] E2 --> E2_POS["Bone density
Lipid metabolism
Neuroprotection"] E2 --> E2_NEG["Gynecomastia
Water retention
Mood instability"] DHT --> DHT_POS["Strength of AR signal
Libido
Neurosteroid effects"] DHT --> DHT_NEG["Acne
Hair loss (genetic)
Prostate growth"] AR --> ANABOLIC["Protein synthesis
Nitrogen retention
Satellite cell activation"] AR --> ERYTHRO["Erythropoiesis
Hematocrit increase"] E2_NEG -.->|"Managed by"| AI["Aromatase Inhibitor
Anastrozole / Letrozole"] DHT_NEG -.->|"Reduced by"| FIN["5-Alpha Reductase Inhibitor
Finasteride / Dutasteride"] style T fill:#e4e4e7,stroke:#3f3f46,stroke-width:3px,color:#0a0a0a style E2 fill:#f4f4f5,stroke:#52525b,stroke-width:2px,color:#0a0a0a style DHT fill:#f4f4f5,stroke:#52525b,stroke-width:2px,color:#0a0a0a style AR fill:#e4e4e7,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style E2_POS fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style E2_NEG fill:#f4f4f5,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style DHT_POS fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style DHT_NEG fill:#f4f4f5,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style ANABOLIC fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style ERYTHRO fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style AI fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#71717a style FIN fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#71717a
Testosterone is not purely anabolic. It is a hormone that is simultaneously anabolic (AR-mediated protein synthesis), estrogenic (aromatization to estradiol), and androgenic (5-alpha reduction to DHT). Every dose increase amplifies all three pathways proportionally. Managing exogenous testosterone means understanding and monitoring all three.
Clinical Research — Peer-Reviewed Evidence
Study Landscape
Testosterone has been studied clinically since its isolation and synthesis in the 1930s. The evidence base covers TRT for hypogonadism, dose-response studies at supraphysiological levels, cardiovascular safety trials, and observational data from enhancement populations. The landmark studies are summarized below.
Dose-Response: The Bhasin Studies
Bhasin et al. (1996)[1] ran the landmark randomized controlled trial showing that supraphysiological testosterone (600 mg/week testosterone enanthate for 10 weeks) increased fat-free mass by 6.1 kg and bench press strength by 9.4 kg in healthy men, even without exercise. The testosterone-plus-exercise group gained 6.1 kg fat-free mass and 22 kg on the squat. This study established that testosterone produces anabolic effects independent of training, and that testosterone plus resistance exercise produces additive effects.
A follow-up dose-response study by Bhasin et al. (2001)[2] gave testosterone enanthate at 25, 50, 125, 300, and 600 mg/week for 20 weeks, with GnRH agonist suppression of endogenous production. The results showed a clear linear dose-response relationship: fat-free mass, muscle size, and strength increased in a dose-dependent way across the entire range. Fat mass dropped at the higher doses. Critically, the study also showed dose-dependent increases in hematocrit, suppression of HDL cholesterol, and increases in LDL cholesterol at the 300 and 600 mg/week doses.
Cardiovascular Safety: The TRAVERSE Trial
The TRAVERSE trial (Lincoff et al., 2023)[3] was a randomized, double-blind, placebo-controlled trial of 5,204 hypogonadal men aged 45-80 with existing cardiovascular disease or high cardiovascular risk. Participants got transdermal testosterone gel or placebo for a mean of 33 months. The primary outcome — major adverse cardiovascular events (MACE: cardiovascular death, nonfatal heart attack, nonfatal stroke) — happened in 7.0% of testosterone-treated men vs 7.3% of placebo, with a hazard ratio of 0.96 (95% CI 0.78-1.17). TRT did not increase MACE in this high-risk population. Testosterone-treated men did have higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism. This trial applies to TRT doses only — supraphysiological doses were not studied.
Testosterone and Mortality in Hypogonadism
Multiple observational studies and meta-analyses have documented that untreated hypogonadism is associated with higher all-cause mortality, cardiovascular mortality, and metabolic syndrome. A meta-analysis by Corona et al. (2011)[4] found low testosterone was associated with a 35% increase in all-cause mortality. TRT in hypogonadal men was associated with reduced mortality in several large retrospective cohort studies, though these are observational and subject to confounding.
Testosterone and Body Composition
A meta-analysis by Corona et al. (2016)[5] pooling 59 RCTs found testosterone therapy in hypogonadal men increased lean body mass by a mean of 1.6 kg and decreased fat mass by 2.0 kg. Effects on metabolic parameters included reduced fasting glucose, HbA1c, and insulin resistance (HOMA-IR). These effects were consistent across TRT doses and formulations.
Testosterone and Bone Mineral Density
The TTrials (Snyder et al., 2017)[6] found that 1 year of testosterone gel in men over 65 with low testosterone increased volumetric bone mineral density at the spine by 7.5% and estimated bone strength by 10.8%, primarily through more trabecular bone. This effect works both directly through AR activation in osteoblasts and indirectly through aromatization to estradiol, which is the primary hormone responsible for bone density in males.
Supraphysiological Doses and Cardiac Remodeling
Baggish et al. (2010)[7] showed that long-term AAS use (including testosterone at supraphysiological doses) was associated with impaired left ventricular systolic function and diastolic dysfunction compared to non-using strength athletes. A follow-up study (Baggish et al., 2017) found reduced midwall fractional shortening in AAS users. These studies are observational and usually involve polypharmacy (multiple AAS compounds), which makes it hard to isolate testosterone's independent cardiac effects at supraphysiological doses.
Study Limitations
- Supraphysiological dose data is limited. Ethical constraints prevent long-term RCTs of testosterone at 500-1000+ mg/week. Most data at these doses comes from short-term trials (Bhasin), observational studies of AAS users, and case reports.
- Polypharmacy confounding. Most studies of AAS-using populations involve multiple compounds, making it impossible to isolate testosterone's independent effects at high doses.
- Duration limitations. Even the TRAVERSE trial (33 months) may be insufficient to capture long-term cardiovascular risk from TRT. Multi-decade data does not exist in RCT form.
- Population bias. TRT trials predominantly study older hypogonadal men. Extrapolation to young eugonadal men using testosterone for enhancement is uncertain.
Common Questions — Dosing Tiers, Ester Comparisons, Bloodwork
Dosing Tiers
TRT / Physiological Replacement (100-200 mg/week)
The goal is to restore serum total testosterone to the mid-normal physiological range (500-900 ng/dL at trough). Most males stabilize within this range at 100-150 mg/week of testosterone enanthate or cypionate, given as one to two intramuscular injections per week. Splitting the dose into two injections (for example, 75 mg every 3.5 days) reduces peak-to-trough swing, which can reduce estrogenic side effects and mood variability. At these doses, most people do not need an aromatase inhibitor. HPTA suppression is complete — endogenous production stops within 2-3 weeks.
Low-Dose Enhancement / First Cycle (200-300 mg/week)
The Bhasin et al. (2001) dose-response study showed that testosterone produces significant lean mass gains well below 500 mg/week. The 125 mg/week group gained about 3.4 kg fat-free mass over 20 weeks — already a meaningful result. At 200-300 mg/week, most people reach supraphysiological serum levels (1200-2000+ ng/dL), significant lean mass accrual, and measurably better strength and recovery — while keeping side effects substantially lower than at 500mg+. This is the range supported by dose-response data for a first cycle based on the 80/20 principle: most of the anabolic benefit with a fraction of the estrogenic, cardiovascular, and androgenic burden. Aromatization is present but manageable — many people at 250 mg/week do not need an aromatase inhibitor. See our First Cycle Guide for the full evidence-based protocol.
Moderate Enhancement (300-500 mg/week)
This range produces significantly supraphysiological serum testosterone (typically 1500-3000+ ng/dL depending on individual response). The Bhasin dose-response data shows continued linear gains — the 300 mg group gained about 5.2 kg FFM and the 600 mg group gained 7.9 kg over 20 weeks. Side effects escalate too: aromatization goes up meaningfully, estradiol management (via bloodwork-guided AI dosing or dose reduction) is more likely to be necessary, androgenic side effects (acne, hair thinning in predisposed people) become more obvious, and HDL suppression is documented at 300+ mg/week. Evidence tier: the Bhasin dose-response data is research-validated (controlled trial).[8] Specific "first cycle" protocol guidance in this range is community-derived, not clinically validated.
High-Dose Enhancement (500-1000+ mg/week)
Anabolic effects continue to rise roughly linearly per the Bhasin dose-response data, but side effects escalate non-linearly. Estradiol levels may reach 2-5 times the physiological range. Hematocrit routinely exceeds 50% and may approach 54%+. HDL cholesterol is typically suppressed by 20-30% or more. Water retention, blood pressure elevation, acne, and androgenic effects are dose-proportional. This dose range is used by advanced enhancement populations and competitive bodybuilders. No long-term safety data exists for sustained use at these levels. The 80/20 analysis: the extra lean mass gained between 300mg and 600mg+ is modest relative to the steep escalation in health costs. Bloodwork frequency should increase to every 4-6 weeks during active use.
Ester Selection
Enanthate vs Cypionate
Functionally interchangeable. Enanthate (half-life 4.5 days) and cypionate (half-life 5 days) produce nearly identical pharmacokinetic profiles. Both are given on the same schedule (every 3.5-7 days). The choice is based on availability, not pharmacological superiority. Cypionate is more commonly prescribed in the United States; enanthate is more common internationally. No clinical trial has shown a meaningful difference in efficacy, side effects, or patient outcomes between them.
Propionate for Stability
Testosterone propionate (half-life 0.8 days) requires every-other-day injection but produces the most stable serum levels of any injectable ester. Some people report fewer estrogenic side effects (water retention, mood swings) on propionate versus enanthate/cypionate at equivalent weekly doses, though controlled data supporting that is limited. The injection frequency makes it less practical for most users. Propionate is more common in short cycles and pre-competition contexts where fast clearance is desired.
Undecanoate for Convenience
Injectable testosterone undecanoate (Nebido) has the longest half-life (20.9 days) and is typically given every 10-14 weeks in clinical TRT. That eliminates frequent injections but produces wider peak-to-trough fluctuation than enanthate/cypionate at more frequent dosing. The oral form (Jatenzo) is taken twice daily with fat and bypasses first-pass hepatic metabolism via lymphatic absorption. Oral undecanoate is FDA-approved for TRT but is not used at supraphysiological doses because of the large number of capsules required and pharmacokinetic limitations.
Bloodwork Protocol
Timing matters: Blood for testosterone, estradiol, and SHBG should always be drawn at trough — immediately before the next scheduled injection. That gives you the lowest point in the dosing cycle and lets you compare blood draws consistently. Drawing at peak (24-48 hours post-injection for enanthate/cypionate) produces inflated values that do not reflect average exposure.
graph LR INJ["Intramuscular
Injection"] INJ --> SUSP["Suspension
No ester
Peak: 2-4 hrs
Duration: <24 hrs"] INJ --> PROP["Propionate
t1/2: 0.8 days
Peak: 24 hrs
Inject: EOD"] INJ --> ENAN["Enanthate
t1/2: 4.5 days
Peak: 48-72 hrs
Inject: 2x/wk"] INJ --> CYP["Cypionate
t1/2: 5 days
Peak: 48-72 hrs
Inject: 2x/wk"] INJ --> UNDEC["Undecanoate
t1/2: 20.9 days
Peak: 7-10 days
Inject: 10-14 wks"] SUSP --> FAST["Fastest clearance
Highest peak
Least stable"] UNDEC --> SLOW["Slowest clearance
Lowest peak
Widest trough"] ENAN --> MID["Most common
Good stability
at 2x/wk dosing"] style INJ fill:#e4e4e7,stroke:#3f3f46,stroke-width:3px,color:#0a0a0a style SUSP fill:#f4f4f5,stroke:#71717a,stroke-width:2px,color:#0a0a0a style PROP fill:#f4f4f5,stroke:#71717a,stroke-width:2px,color:#0a0a0a style ENAN fill:#e4e4e7,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style CYP fill:#f4f4f5,stroke:#52525b,stroke-width:2px,color:#0a0a0a style UNDEC fill:#f4f4f5,stroke:#71717a,stroke-width:2px,color:#0a0a0a style FAST fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#71717a style SLOW fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#71717a style MID fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a
Risk Profile Analysis — Estrogenic, Androgenic, Cardiovascular, HPTA
Testosterone's side effect profile is dose-dependent. The analysis below separates risk by physiological system and indicates severity at TRT versus supraphysiological doses. Each system is rated: Negligible, Mild, Moderate, or Significant.
Estrogenic Effects
TRT: Mild | Supraphysiological: Moderate to Significant
Testosterone aromatizes to estradiol in a dose-proportional way. At TRT doses, estradiol typically stays within the normal male range (15-40 pg/mL by sensitive LC-MS/MS assay) and does not need intervention. At 300-500 mg/week, estradiol may reach 50-80+ pg/mL, producing water retention, bloating, nipple sensitivity, and mood changes. At 500-1000+ mg/week, estradiol can exceed 100 pg/mL, raising the risk of gynecomastia (proliferation of breast glandular tissue — once established, requires surgical removal). Aromatase inhibitors (anastrozole 0.25-0.5 mg every other day) reduce estradiol but carry their own risks: joint pain, lipid damage (HDL reduction), bone density loss, and impaired glucose metabolism. AI use should be guided by bloodwork and symptoms, never preemptive protocol.
Androgenic Effects
TRT: Mild | Supraphysiological: Moderate
DHT-mediated side effects are proportional to testosterone dose and individual 5-alpha reductase activity. Acne (especially back and shoulders) results from androgen-stimulated sebum production. Androgenetic alopecia (male pattern hair loss) is accelerated in genetically predisposed people — DHT binds to follicular androgen receptors and triggers miniaturization of scalp hair follicles. This is irreversible once follicles are lost. Prostate effects: testosterone does not cause prostate cancer based on current evidence, but it stimulates growth of existing prostate tissue and can increase PSA. Men with confirmed prostate cancer should not use exogenous testosterone. Body and facial hair growth increases with androgen exposure.
Cardiovascular Effects
TRT: Mild | Supraphysiological: Significant
Cardiovascular risk from testosterone is dose-dependent and multifactorial:
- Lipids: Testosterone at TRT doses has modest or neutral effects on lipids. At supraphysiological doses, HDL cholesterol is consistently suppressed by 20-30%. LDL may increase. This shift toward an atherogenic lipid profile is one of the most well-documented cardiovascular risks of supraphysiological androgen use.
- Hematocrit: Testosterone stimulates erythropoiesis dose-dependently. Hematocrit above 54% increases blood viscosity and thromboembolic risk. This is the most acute cardiovascular risk of testosterone therapy and is the primary reason for regular CBC monitoring. Therapeutic phlebotomy (blood donation) or dose reduction is the standard intervention.
- Blood pressure: Supraphysiological testosterone causes sodium and water retention via mineralocorticoid and estrogenic pathways, which can elevate blood pressure. This effect is more pronounced at higher doses and in individuals with pre-existing hypertension or high body fat (greater aromatization).
- Left ventricular hypertrophy: Observational data suggests long-term supraphysiological AAS use is associated with concentric left ventricular hypertrophy and impaired diastolic function. Whether this is attributable to testosterone specifically or to the combination of multiple AAS, training stimulus, and other factors (GH, insulin) is unclear.
HPTA Suppression
TRT: Complete | Supraphysiological: Complete
graph TD HYPO["Hypothalamus
GnRH pulse generator"] PIT["Anterior Pituitary
Gonadotroph cells"] TEST["Testes
Leydig cells"] ENDO_T["Endogenous Testosterone
5-7 mg/day"] EXO_T["Exogenous Testosterone
Injected / Applied"] HYPO -->|"GnRH
pulsatile"| PIT PIT -->|"LH"| TEST PIT -->|"FSH"| SPERM["Sertoli Cells
Spermatogenesis"] TEST --> ENDO_T ENDO_T -->|"Negative feedback
to hypothalamus"| HYPO ENDO_T -->|"Negative feedback
to pituitary"| PIT EXO_T -->|"Same negative
feedback signal"| HYPO EXO_T -->|"Same negative
feedback signal"| PIT EXO_T -->|"Suppresses"| SUPPRESS["LH/FSH = Near Zero
Endogenous T = Near Zero
Spermatogenesis = Impaired"] SUPPRESS -.->|"Recovery
after cessation"| PCT["PCT Options
Clomiphene / Tamoxifen / hCG"] PCT -.->|"Stimulates"| PIT style HYPO fill:#e4e4e7,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style PIT fill:#f4f4f5,stroke:#52525b,stroke-width:2px,color:#0a0a0a style TEST fill:#f4f4f5,stroke:#52525b,stroke-width:2px,color:#0a0a0a style ENDO_T fill:#f4f4f5,stroke:#71717a,stroke-width:2px,color:#0a0a0a style EXO_T fill:#e4e4e7,stroke:#3f3f46,stroke-width:3px,color:#0a0a0a style SPERM fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#0a0a0a style SUPPRESS fill:#f4f4f5,stroke:#3f3f46,stroke-width:2px,color:#0a0a0a style PCT fill:#f4f4f5,stroke:#a1a1aa,stroke-width:1px,color:#71717a
Hepatic Effects
TRT: Negligible | Supraphysiological: Negligible
Injectable testosterone esters are not hepatotoxic. They bypass first-pass hepatic metabolism entirely. Liver enzyme elevations (AST, ALT) seen in testosterone users are almost always from resistance training-induced muscle damage (AST is released from skeletal muscle, not just liver). Oral methyltestosterone and other 17-alpha alkylated steroids are hepatotoxic, but those are different compounds. Oral testosterone undecanoate (Jatenzo) is absorbed via the lymphatic system and does not carry the hepatotoxicity of 17-alpha alkylated steroids.
Psychological Effects
TRT: Mild (generally positive) | Supraphysiological: Variable
At TRT doses, testosterone typically improves mood, motivation, energy, and libido in hypogonadal men. At supraphysiological doses, psychological effects become variable: some people report more confidence and drive; others experience irritability, aggression, anxiety, or mood instability, especially when estradiol is uncontrolled. The "roid rage" stereotype is overstated in the literature — large-scale studies show most people on supraphysiological testosterone do not show clinically significant aggression. Individual susceptibility varies, and pre-existing psychiatric conditions may get worse.
Fertility warning: Exogenous testosterone at any dose suppresses sperm production. In some men, testosterone use causes azoospermia (zero sperm count). Recovery of sperm production after stopping can take 6-24+ months and may be incomplete, particularly after prolonged use. Men who want to preserve fertility should discuss hCG co-administration with their physician or avoid exogenous testosterone entirely. Testosterone is not a male contraceptive and should not be used for birth control — suppression of sperm production is variable and incomplete in many users.
- Hematocrit / CBC — every 3-6 months (TRT) or every 4-6 weeks (supraphysiological). Action threshold: >54%.
- Estradiol (sensitive LC-MS/MS) — every blood draw. Do not use standard immunoassay in males.
- Lipid panel — every 3-6 months. HDL suppression is the primary concern at supraphysiological doses.
- Blood pressure — monitor at home regularly. Target below 130/80 mmHg.
- PSA — annually for men 40+ or those with family history of prostate cancer.
- Liver enzymes — baseline and annually. Expect mild AST elevation from training.
- Fasting glucose / HbA1c — annually or more frequently if metabolic risk factors present.
Evidence Synthesis — Balancing Documented Effects
Efficacy Summary
Testosterone is the most well-characterized anabolic agent in existence. The dose-response relationship for lean mass, strength, and body composition is established by RCT data across the full dose range from 25 to 600 mg/week. The anabolic effect is linear and dose-dependent. At TRT doses (100-200 mg/week), the primary benefit is restoration of physiological function — mood, libido, energy, body composition, and bone density — in hypogonadal men. At supraphysiological doses (300-1000+ mg/week), testosterone produces substantial increases in muscle mass and strength that go beyond what is achievable naturally, with the magnitude proportional to dose.
Risk Summary
At TRT doses, the risk profile is well-characterized and manageable with standard monitoring. The TRAVERSE trial showed no increase in MACE in high-risk hypogonadal men over 33 months. The primary risks at TRT doses are hematocrit elevation (manageable), HPTA suppression (expected and accepted), and fertility impairment. At supraphysiological doses, the risk profile shifts substantially: HDL suppression, hematocrit elevation, blood pressure increase, estrogenic side effects, androgenic side effects, and complete HPTA suppression with uncertain recovery. Long-term RCT data at supraphysiological doses does not exist, and observational data from AAS-using populations is confounded by polypharmacy.
Risk-Benefit Assessment by Tier
| Dose Tier | Primary Benefit | Primary Risk | Risk-Benefit Assessment |
|---|---|---|---|
| TRT (100-200 mg/wk) | Physiological restoration; quality of life; body composition | HPTA suppression (expected); hematocrit elevation; fertility impairment | Favorable for confirmed hypogonadism under medical supervision |
| Moderate (300-500 mg/wk) | Significant muscle mass and strength gains beyond natural limits | HDL suppression; estrogen management required; androgenic sides | Individual decision; manageable risks with proper monitoring |
| High (500-1000+ mg/wk) | Maximum anabolic response; competitive bodybuilding | Substantial cardiovascular strain; difficult estrogen control; uncertain long-term cardiac effects | High risk; no long-term safety data; used by advanced enhancement populations |
Testosterone is not inherently dangerous or inherently safe. It is a hormone with a dose-dependent risk profile. The same compound that restores quality of life in a hypogonadal man at 150 mg/week produces substantial cardiovascular strain at 1000 mg/week. The dose defines the risk. The individual defines the threshold of acceptable risk. Informed consent requires understanding both.
For Physique Enhancement
Testosterone is the foundation of every anabolic steroid cycle. No other compound replicates its full spectrum of effects: direct AR-mediated anabolism, estrogen-mediated benefits to bone and lipids, neurosteroid activity, erythropoiesis, and maintenance of libido and well-being. In physique enhancement, testosterone serves as either the sole compound or the base on which other AAS are added.
Testosterone-Only Cycles
A testosterone-only cycle is the standard first cycle among informed practitioners. The rationale is sound: testosterone is the most well-studied AAS, produces predictable dose-response effects (Bhasin et al., 2001), has a well-characterized side effect profile, and provides the baseline androgen needed for sexual function, mood, and well-being. Using a single compound lets you identify how your body responds to exogenous androgens — including aromatization rate, androgenic sensitivity, and HPTA recovery capacity — before adding more variables. The Bhasin dose-response data supports 250 mg/week for 16-20 weeks as the minimum effective dose range — see our First Cycle Guide for the full evidence-based rationale, including the dose-response data showing meaningful gains at doses well below the historically cited 500 mg/week.
Testosterone as a Base Compound
In multi-compound cycles, testosterone is included as a "base" to maintain physiological androgen and estrogen levels. Even when other AAS provide the primary anabolic stimulus, testosterone ensures that the downstream metabolites — particularly estradiol — remain present. Estradiol is essential for libido, joint function, bone density, lipid metabolism, and neurological function. Running other AAS without a testosterone base frequently produces "crashed estrogen" symptoms: dry joints, low libido, depression, and bad lipid profiles. The typical testosterone base dose in multi-compound protocols is 100-200 mg/week (TRT dose), with the other compound(s) providing the supraphysiological anabolic stimulus.
Dose-Response for Lean Mass
Evidence tier: Research-validated. Bhasin et al. (2001)[8] gave testosterone enanthate at 25, 50, 125, 300, and 600 mg/week to healthy young men for 20 weeks with GnRH agonist suppression of endogenous production. Fat-free mass changes by dose group:
- 25 mg/week (sub-physiological): Fat-free mass decreased slightly (insufficient androgen replacement)
- 50 mg/week (low-normal replacement): Minimal change — approximately replacement-level
- 125 mg/week (high-normal replacement): +3.4 kg fat-free mass — significant gain at a dose many would consider "just TRT"
- 300 mg/week: +5.2 kg fat-free mass
- 600 mg/week: +7.9 kg fat-free mass
The 80/20 insight: The 125 mg group gained 3.4 kg FFM. The 600 mg group gained 7.9 kg — only 2.3x the result at 4.8x the dose. Meanwhile, estradiol, hematocrit, HDL suppression, and androgenic effects escalated continuously with dose. The greatest return on investment (lean mass gained per unit of health cost) is at the lower end of the supraphysiological range. That is why the dose-response data supports 250 mg/week as the minimum effective dose for a first cycle, not 500 mg. See our First Cycle Guide for the full analysis.
Individual response varies based on training history, nutrition, genetics, and androgen receptor density. Later cycles at the same dose produce diminishing returns as the lifter approaches their genetic ceiling for androgen-supported muscle mass.
During Caloric Deficits (Cutting)
Testosterone at TRT or moderate doses during caloric restriction preserves lean mass that would otherwise be lost. The anti-catabolic effect — keeping protein synthesis rates elevated and nitrogen balance positive despite energy deficit — is one of the main reasons testosterone is kept year-round by many enhancement users. Without testosterone during a cut, cortisol-mediated catabolism accelerates and the deficit disproportionately hits lean tissue.
Tool link: Use the Testosterone Dose-Response Explorer to model expected blood levels and lean mass outcomes at different doses, and the Steroid Plotter to visualize blood level curves across esters and injection frequencies.
For Cognitive Enhancement
Testosterone is a neurosteroid with established effects on brain structure and function. The relationship between testosterone and cognition is not linear — both deficiency and excess produce cognitive impairment, following an inverted-U dose-response curve.
Testosterone Deficiency and Cognitive Decline
Hypogonadism is associated with impaired spatial memory, reduced verbal fluency, slower processing speed, and higher risk of depressive symptoms. Multiple observational studies have linked low testosterone to increased risk of Alzheimer's disease and cognitive decline in aging men. The TTrials cognitive function study found modest but statistically non-significant improvements in cognition with 1 year of TRT in men over 65, suggesting TRT may slow cognitive decline but is not a strong cognitive enhancer on its own.
Physiological Restoration (TRT) and Cognition
Restoring testosterone to the mid-normal range in hypogonadal men consistently improves mood, motivation, verbal memory, and spatial cognition in clinical trials. These effects are biggest in men with the lowest baseline testosterone. The cognitive benefits of TRT are secondary to the restoration of normal neurosteroid signaling — testosterone modulates GABA and glutamate neurotransmission, serotonin receptor expression, and dopaminergic function. Estradiol (derived from testosterone via aromatase in the brain) is neuroprotective and essential for hippocampal synaptic plasticity and memory consolidation.
Supraphysiological Testosterone and Cognition
The evidence for cognitive effects at supraphysiological doses is limited and mixed. Some studies report impaired cognitive flexibility and more impulsivity at high androgen levels. Others report enhanced confidence, drive, and stress tolerance. The inverted-U model predicts that pushing testosterone far above the physiological range does not further improve cognition and may impair executive function, working memory, and emotional regulation. Supraphysiological estradiol (from more aromatization) may contribute to mood instability and cognitive fog in some people. No evidence supports testosterone as a cognitive performance-enhancing drug at supraphysiological doses.
Estradiol and Neuroprotection
A substantial portion of testosterone's neuroprotective effects work through its conversion to estradiol in the brain. Brain aromatase is expressed in the hippocampus, prefrontal cortex, and amygdala. Estradiol promotes BDNF expression, supports synaptic plasticity, protects against oxidative neuronal damage, and modulates neuroinflammation. Aggressive estrogen suppression with aromatase inhibitors during testosterone therapy may inadvertently impair these neuroprotective mechanisms. That is an additional reason to avoid preemptive AI use at TRT doses.
Practical note: For cognitive optimization, the evidence supports keeping testosterone in the mid-to-upper physiological range (600-900 ng/dL) with estradiol in the normal male range (20-35 pg/mL by sensitive assay). That gives you the neurosteroid benefits of both testosterone and estradiol without the cognitive impairments from deficiency or excess. Supraphysiological doses do not appear to enhance cognition and may impair it.
Conclusions and Dosage Protocols
Mechanism: Testosterone binds the androgen receptor to drive protein synthesis and nitrogen retention. It is simultaneously converted to estradiol (via aromatase) and DHT (via 5-alpha reductase), producing estrogenic and androgenic effects proportional to dose. It suppresses the HPTA via negative feedback, halting endogenous production and impairing sperm production. It stimulates red blood cell production, increasing hematocrit dose-dependently.
Evidence: The dose-response relationship is established by RCT data (Bhasin et al., 1996, 2001). TRT safety is supported by the TRAVERSE trial (no increase in MACE over 33 months in high-risk hypogonadal men). Supraphysiological dose safety data is limited to short-term trials and observational studies confounded by polypharmacy. The anabolic efficacy of testosterone at all dose levels is not in question — it is among the most well-documented pharmacological effects in medicine.
Conclusion: Testosterone is the reference AAS. At TRT doses, it is a medically indicated treatment for hypogonadism with a favorable risk-benefit profile under monitoring. At supraphysiological doses, it produces substantial anabolic effects with dose-proportional health risks that require active management. This article presents the evidence for all dosing tiers. The decision to use testosterone — and at what dose — is an individual risk-benefit calculation that should be made with full knowledge of the pharmacology, the monitoring requirements, and the potential consequences.
Legal and medical disclaimer: Testosterone is a Schedule III controlled substance in the United States and a controlled substance in most jurisdictions worldwide. Use without a valid prescription is illegal. All dosing information in this article is presented for educational purposes based on published clinical and pharmacological data. Protocols.is does not advocate for, encourage, or facilitate the illegal use of controlled substances. Any decision to use testosterone should involve a qualified physician, comprehensive bloodwork, and full informed consent regarding the legal, medical, and personal risks involved.
Frequently Asked Questions
Yes, and in many cases it should be. At TRT doses (100-200 mg/week), most men do not need an AI. Estradiol typically stays within the physiological range. Unnecessary AI use at TRT doses suppresses estradiol too far, hurting lipid metabolism, bone density, libido, joint lubrication, and neurological function. At supraphysiological doses (300+ mg/week), some people develop estrogenic symptoms (nipple sensitivity, water retention, gynecomastia) that warrant AI use. The decision should be guided by sensitive estradiol bloodwork and symptoms — not preemptive protocol. Start without an AI and add only if bloodwork or symptoms dictate.
Hematocrit above 54% increases blood viscosity and the risk of clots (stroke, deep vein thrombosis, pulmonary embolism, heart attack). If hematocrit exceeds 54%, the standard interventions are: (1) therapeutic phlebotomy (blood donation removes red blood cells and reduces hematocrit), (2) testosterone dose reduction, (3) more frequent injections (smaller, more frequent doses produce lower peak testosterone and less erythropoietic stimulation), and (4) adequate hydration (dehydration artificially concentrates hematocrit). Some people are high responders to testosterone's erythropoietic effect and may struggle to keep hematocrit below 54% even at TRT doses. That is a genuine contraindication that may require dose limitation.
Current evidence does not support a causal relationship between testosterone therapy and prostate cancer initiation. The "androgen hypothesis" (Huggins, 1941) — which proposed that testosterone drives prostate cancer — has been substantially revised. The saturation model (Morgentaler, 2006) proposes that prostate tissue androgen receptors saturate at relatively low testosterone levels (about 250 ng/dL), and that increasing testosterone beyond that level does not further stimulate prostate growth. Multiple meta-analyses of TRT trials have found no increased incidence of prostate cancer in testosterone-treated men. Testosterone does stimulate growth of existing prostate cancer, and exogenous testosterone is contraindicated in men with active or suspected prostate cancer. PSA monitoring remains appropriate.
Testosterone enanthate and cypionate can be given via intramuscular (IM) or subcutaneous (SubQ) injection. Multiple studies (Al-Futaisi et al., 2006; Olsson et al., 2014) have shown subcutaneous injection produces equivalent serum testosterone levels to intramuscular injection at the same dose. SubQ injection uses a shorter needle (typically 27-30 gauge, 0.5 inch), is less painful, and can go into abdominal fat. Some clinicians prefer SubQ for TRT because of patient comfort and equivalent pharmacokinetics. At higher volumes (above 0.5 mL per injection site), IM injection is generally preferred to avoid SubQ depot nodules.
References
- Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7. PubMed
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181. PubMed
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PubMed
- Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165(5):687-701. PubMed
- Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest. 2016;39(9):967-981. PubMed
- Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial. JAMA Intern Med. 2017;177(4):471-479. PubMed
- Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail. 2010;3(4):472-476. PubMed
- Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678-688. PubMed
Stop guessing. Get the Framework.
Every compound on this site is one piece. The Framework is the whole system — interaction checker, protocol explorer, biomarker tracker, weekly check-in, and pre-built protocols across every major goal. Evidence-based. No broscience. One place. One price.